Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07108998Phase 2Recruiting

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Role: lead

NCT07014917Phase 2Recruiting

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Role: lead

NCT06978088Phase 2Recruiting

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Role: lead

All 3 trials loaded